Comparing PMV Pharmaceuticals (NASDAQ:PMVP) and BioCryst Pharmaceuticals (NASDAQ:BCRX)

PMV Pharmaceuticals (NASDAQ:PMVP) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.

Institutional and Insider Ownership

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

PMV Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for PMV Pharmaceuticals and BioCryst Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1	0	1	1	2.67
BioCryst Pharmaceuticals	0	3	9	0	2.75

PMV Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 371.70%. BioCryst Pharmaceuticals has a consensus target price of $20.70, indicating a potential upside of 128.48%. Given PMV Pharmaceuticals’ higher probable upside, equities analysts clearly believe PMV Pharmaceuticals is more favorable than BioCryst Pharmaceuticals.

Valuation & Earnings

This table compares PMV Pharmaceuticals and BioCryst Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74 million	($1.49)	-0.71
BioCryst Pharmaceuticals	$874.84 million	2.63	$263.86 million	($1.78)	-5.09

BioCryst Pharmaceuticals has higher revenue and earnings than PMV Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PMV Pharmaceuticals and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Summary

PMV Pharmaceuticals beats BioCryst Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.